Roy S. Herbst, deputy director of Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at Yale School of Medicine, was elected to the Friends of Cancer Research Board of Directors.
Herbst is an expert in lung cancer treatment and research. His research is focused on developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular, the process of linking genetic abnormalities of cancer cells to novel therapies, and his work to bring immunotherapy to the forefront of treatment options for lung cancer.
His work involves identifying tumor biomarkers and bringing novel targeted treatments and immunotherapies to patients.
“Dr. Herbst’s incredible scientific expertise and dedication to patients will be an invaluable asset for the organization,” Ellen Sigal, Friends’ chair and founder, said in a statement.
“He has been integral to many projects over the years, including the Lung Cancer Master Protocol project and the new generation of Pragmatic Clinical Trials,” Jeff Allen, president and CEO of Friends, said in a statement.
